The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for $9.5 billion, sending shares of the Cambridge, Mass.-based biopharma firm soaring in premarket trading.

The pharma giant wants to refreshen its portfolio after some of its internal development programs disappointed in clinical trials.